Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands

Renaud J.S.D. Heine*, Ron H.J. Mathijssen, Floor A.J. Verbeek, Chantal Van Gils, Carin A. Uyl-de Groot

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

Fingerprint

Dive into the research topics of 'Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science